Fate Therapeutics, Inc. (FATE)
Healthcare
- Fundamental
- 2
- Sentiment
- 3
- Technical
- 3
Do Nothing: fundamentalScore is 2 (below required floor of 3); the strategy requires fundamentalScore ≥ 3 before any bullish entry. Liquidity and event checks pass, but the chart is only mixed with price still under the short-term moving-average cluster.
Company overview
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing programmed cellular immunotherapies for cancer and immune disorders. Its pipeline includes NK- and T-cell immuno-oncology programs targeting various cancers, such as acute myeloid leukemia and multiple myeloma. The company collaborates with Ono Pharmaceutical and Juno Therapeutics to advance its research efforts.
Fundamental
weakFate Therapeutics faces high cash burn and negative profitability, with minimal revenue and significant dilution risk.
Clinical-stage biotech with volatile/declining collaboration revenue and sustained losses/cash burn. SEC filings show ~$174.82M in cash and short-term investments (2026-03-31) with management guiding to at least 12 months of runway, but cash burn remains material (FY2025 operating cash outflow about $106M). Profitability is deeply negative and most earnings-based valuation metrics are not meaningful; EV/Sales is very high (~43.91x) and free-cash-flow yield is negative (~-45.02%). High clinical/regulatory and dilution risk drives the risk profile despite supportive analyst targets.
Sentiment
fairMedia coverage is mildly positive but sparse, with no clear near-term catalysts identified.
Last-14d media tone is mildly bullish but thin, while the only clearly actionable near-term item is a 2026-06-15 SEC 8-K increasing the equity incentive plan share reserve (potential dilution overhang; regulator_confirmed). Baseline (30–90d) coverage is modestly bullish/mixed on the FT819/FT839 pipeline and the legal screen surfaced no cases or confirmed investigations, leaving a forming setup without a defined forward catalyst.
Technical
fairThe broader recovery trend is intact, but short-term trend repair is incomplete with price below key moving averages.
FATE is in a mixed technical state. The latest daily snapshot near 2.00 remains above the 50-day SMA (1.94) and 200-day SMA (1.38), so the broader recovery from the spring lows is still intact, but price is still under the short-term 20-day/EMA9-EMA21 cluster after the June pullback. Momentum is neutral-to-soft with RSI14 at 48.79, Williams %R at -64.78, and a derived MACD that is essentially flat to slightly negative versus its signal, while ADX14 at 32.8 says the recent swing still has real force rather than a clean upside reset.
You’re looking at 2026-06-26 — about 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.